AXS-05 + Bupropion

ApprovedRecruiting
0 watching 0 views this week๐Ÿ”ฅ Hot
82
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Major Depressive Disorder

Conditions

Major Depressive Disorder

Trial Timeline

Dec 27, 2023 โ†’ Mar 1, 2026

About AXS-05 + Bupropion

AXS-05 + Bupropion is a approved stage product being developed by Axsome Therapeutics for Major Depressive Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06223880. Target conditions include Major Depressive Disorder.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (3)

NCT IDPhaseStatus
NCT06223880ApprovedRecruiting
NCT03595579Phase 2Completed
NCT02741791Phase 3Completed

Competing Products

20 competing products in Major Depressive Disorder

See all competitors
ProductCompanyStageHype Score
Duloxetine HydrochlorideEli LillyPre-clinical
23
LY2216684Eli LillyPhase 1
33
LY2216684Eli LillyPhase 1
33
DuloxetineEli LillyPhase 3
77
LY2216684 + DigoxinEli LillyPhase 1
33
Duloxetine + ParoxetineEli LillyPhase 3
77
Duloxetine + placeboEli LillyPhase 3
77
LY2216684 + Placebo + EscitalopramEli LillyPhase 2
52
FK949EAstellas PharmaPhase 1
33
quetiapine extended release (XR) + PlaceboAstellas PharmaPhase 2
52
FK949EAstellas PharmaPhase 1
33
FK949EAstellas PharmaPhase 1
33
FK949EAstellas PharmaPhase 1
33
Mirtazapine TabletsSun PharmaceuticalApproved
85
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1Ono PharmaceuticalPhase 2
52
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
Pramipexole ER + EscitalopramCiplaPhase 2
52
LY2216684 + SertralineEli LillyPhase 1
33
LY2216684 + Placebo + LorazepamEli LillyPhase 1
33
LY2216684 + SSRIEli LillyPhase 3
77